Forxiga
| Name | Forxiga |
|---|---|
| Active Substance | dapagliflozin propanediol monohydrate |
| Prescription | na recept |
| Type of prescription | ponovljivi recept |
| Distribution | u ljekarni |
| ATC Code | A10BK01 |
| Medicinal product marketed in the Croatia | Da |
| Educational materials for healthcare professionals |
Vodič za zdravstvene radnike, verzija 2 |
| Educational materials for patients / caregivers |
Vodič za bolesnike sa šećernom bolešću tipa 1 i njegovatelje, verzija 1 Kartica s upozorenjima za bolesnika, verzija 1 |
Note
The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga
The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o riziku od Fournierove gangrene kod primjene lijekova koji sadrže inhibitore SGLT2 | 22.01.2019 | AstraZeneca d.o.o., Boehringer Ingelheim Zagreb d.o.o. |
| Pismo zdravstvenim radnicima s ažuriranim informacijama o riziku od dijabetičke ketoacidoze tijekom liječenja inhibitorima SGLT2 (Invokana*, Vokanamet*, Forxiga, Xigduo, Jardiance, Synjardy*) | 14.03.2016 | AstraZeneca AB, Boehringer Ingelheim International GmbH i Janssen Cilag International N.V. |
